NASDAQ:APOP - Cellect Biotechnology Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.15
▼ -0.14 (-6.11%)
1 month | 3 months | 12 months
Get New Cellect Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APOP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APOP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cellect Biotechnology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.15.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Cellect Biotechnology. This rating has held steady since November 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2018HC WainwrightSet Price TargetBuy$12.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/29/2018HC WainwrightReiterated RatingBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/16/2018HC WainwrightSet Price TargetBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/6/2018HC WainwrightSet Price TargetBuy$14.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/29/2018HC WainwrightReiterated RatingBuy$14.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/5/2018HC WainwrightSet Price TargetBuy$14.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
9/25/2017HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $14.00Medium
i
Rating by R. Selvaraju at HC Wainwright
4/4/2017Rodman & RenshawReiterated RatingBuy$10.00 ➝ $1.00High
i
3/27/2017HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/22/2017HC WainwrightSet Price TargetBuy$10.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
11/10/2016Rodman & RenshawInitiated CoverageBuy$10.00N/A
i
(Data available from 4/21/2016 forward)
Cellect Biotechnology logo
Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel.
Read More

Today's Range

Now: $2.15
$2.10
$2.36

50 Day Range

MA: $3.24
$2.29
$4.77

52 Week Range

Now: $2.15
$1.65
$7.15

Volume

153,299 shs

Average Volume

1,714,534 shs

Market Capitalization

$4.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellect Biotechnology?

The following Wall Street analysts have issued reports on Cellect Biotechnology in the last year:
View the latest analyst ratings for APOP.

What is the current price target for Cellect Biotechnology?

0 Wall Street analysts have set twelve-month price targets for Cellect Biotechnology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cellect Biotechnology in the next year.
View the latest price targets for APOP.

What is the current consensus analyst rating for Cellect Biotechnology?

Cellect Biotechnology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for APOP.

What other companies compete with Cellect Biotechnology?

How do I contact Cellect Biotechnology's investor relations team?

Cellect Biotechnology's physical mailing address is 23 HATA`AS STREET, KFAR SABA L3, 44425. The company's listed phone number is 972-9974-1444 and its investor relations email address is [email protected] The official website for Cellect Biotechnology is www.cellect.co.